{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:58:44Z","timestamp":1790657924522,"version":"4.1.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the real-world effectiveness and safety of lasmiditan and determine the factors associated with its effectiveness and adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated 75 migraine patients (15 males and 60 females; age 44.0\u202f\u00b1\u202f12.4\u202fyears), including 20 (35.1%) with chronic migraine, who completed a questionnaire in a single-center setting. Headache severity before and after taking lasmiditan was scored using a numerical rating scale (NRS), and changes in pain and most bothersome symptoms (MBS) were assessed over time. Adverse effects such as drowsiness, weakness, and dizziness, as well as preferences, were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The response rate was 76% (57\/75 patients, 180 attacks). Headache improvement was observed in 61.3% (100\/144 attacks) at 2\u202fh and 73.0% (119\/151 attacks) at 24\u202fh, with headache resolution rates of 27.8% (50\/144 attacks) and 43.9% (71\/151 attacks), respectively. Compared with patients who did not receive anti-CGRP monoclonal antibodies, patients who received anti-CGRP monoclonal antibodies had higher 2-h headache improvement rates (77.0% vs. 57.9%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.015). MBS improved by 56.9% at 60\u202fmin and 70.8% at 24\u202fh. Adverse effects occurred in 81.3% of the patients, most commonly somnolence (39.4%), followed by weakness (32.2%) and dizziness (19.4%). Patients without somnolence had higher 24-h headache improvement rates than those with somnolence did (78.3% vs. 52.9%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). Despite frequent adverse effects, 25% of patients (19\/75) used lasmiditan as their sole treatment for acute attacks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Lasmiditan demonstrated meaningful effectiveness in a real-world setting, although adverse effects were common.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1968634","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:37:49Z","timestamp":1790656669000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness and safety of lasmiditan in patients with migraine: an observational study"],"prefix":"10.3389","volume":"17","author":[{"given":"Saro","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Neurology, Dokkyo Medical University","place":["Mibu, Japan"]},{"name":"Stroke Center, Dokkyo Medical University Hospital","place":["Mibu, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dokkyo Medical University","place":["Mibu, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukuto","family":"Shioda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dokkyo Medical University","place":["Mibu, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Shiina","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dokkyo Medical University","place":["Mibu, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dokkyo Medical University","place":["Mibu, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Sakuramoto","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dokkyo Medical University","place":["Mibu, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Hida","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dokkyo Medical University","place":["Mibu, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dokkyo Medical University","place":["Mibu, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of Disease study 2016","volume":"390","author":"Disease","year":"2017","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3331024241252666","DOI":"10.1177\/03331024241252666","article-title":"International headache society global practice recommendations for the acute pharmacological treatment of migraine","volume":"44","author":"Puledda","year":"2024","journal-title":"Cephalalgia"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1177\/0333102413480756","article-title":"Triptan nonresponders: do they exist and who are they?","volume":"33","author":"Viana","year":"2013","journal-title":"Cephalalgia"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/0333102410370873","article-title":"Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan","volume":"30","author":"Nelson","year":"2010","journal-title":"Cephalalgia"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s00415-025-13202-0","article-title":"Influence of triptans use on anti-CGRP mAbs response: a prospective, cohort study","volume":"272","author":"Vollono","year":"2025","journal-title":"J Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s10194-020-01132-3","article-title":"Lasmiditan mechanism of action\u2014review of a selective 5-HT(1F) agonist","volume":"21","author":"Clemow","year":"2020","journal-title":"J Headache Pain"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The international classification of headache disorders","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","article-title":"Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study","volume":"91","author":"Kuca","year":"2018","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/0333102421989232","article-title":"Randomized, controlled trial of lasmiditan over four migraine attacks: findings from the CENTURION study","volume":"41","author":"Ashina","year":"2021","journal-title":"Cephalalgia"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2515816320958176","DOI":"10.1177\/2515816320958176","article-title":"Long-term safety and efficacy of lasmiditan for acute treatment of migraine: final results of the GLADIATOR study","volume":"3","author":"Brandes","year":"2020","journal-title":"Cephalalgia Rep"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/brain\/awz134","article-title":"Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine","volume":"142","author":"Goadsby","year":"2019","journal-title":"Brain"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"3331024241258695","DOI":"10.1177\/03331024241258695","article-title":"Efficacy and tolerability of 100 mg of lasmiditan for migraine: a multi-center, prospective observational real-world study in Japan","volume":"44","author":"Ishii","year":"2024","journal-title":"Cephalalgia"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3988\/jcn.2025.0021","article-title":"Real-world experience of Lasmiditan for the acute treatment of migraine","volume":"21","author":"Jeong","year":"2025","journal-title":"J Clin Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3390\/neurolint17050062","article-title":"Identifying factors associated with the efficacy of Lasmiditan 50 mg as an acute treatment for migraine attacks under various dosing conditions in real-world clinical practice","volume":"17","author":"Tanei","year":"2025","journal-title":"Neurol Int"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3390\/neurolint16030048","article-title":"Efficacy of Lasmiditan as a secondary treatment for migraine attacks after unsuccessful treatment with a triptan","volume":"16","author":"Shibata","year":"2024","journal-title":"Neurol Int"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s10194-024-01904-1","article-title":"Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis","volume":"25","author":"Laohapiboolrattana","year":"2024","journal-title":"J Headache Pain"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1177\/0333102415610874","article-title":"The influence of genetic constitution on migraine drug responses","volume":"36","author":"Christensen","year":"2016","journal-title":"Cephalalgia"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10194-010-0241-0","article-title":"Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine","volume":"11","author":"Gentile","year":"2010","journal-title":"J Headache Pain"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/03331024211048507","article-title":"Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: findings from the CENTURION study","volume":"42","author":"Reuter","year":"2022","journal-title":"Cephalalgia"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"25158163251355591","DOI":"10.1177\/25158163251355591","article-title":"Comparison of the adverse events of preprandial and postprandial lasmiditan intake: a retrospective chart review","volume":"8","author":"Tatsuoka","year":"2025","journal-title":"Cephalalgia Rep"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/head.13544","article-title":"Characterization of dizziness after lasmiditan usage: findings from the SAMURAI and SPARTAN acute migraine treatment randomized trials","volume":"59","author":"Tepper","year":"2019","journal-title":"Headache"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40263-022-00928-y","article-title":"The association between the occurrence of common treatment-emergent adverse events and efficacy outcomes after Lasmiditan treatment of a single migraine attack: secondary analyses from four pooled randomized clinical trials","volume":"36","author":"Doty","year":"2022","journal-title":"CNS Drugs"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1097\/j.pain.0000000000001801","article-title":"Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system","volume":"161","author":"Labastida-Ramirez","year":"2020","journal-title":"Pain"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1968634\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:37:58Z","timestamp":1790656678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1968634\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":23,"alternative-id":["10.3389\/fneur.2026.1968634"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1968634","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"1968634"}}